Consistent with this notion, a higher percentage of CD133+/EpCAM+ CSCs that express PD-L1 were observed in the lymph nodes of NSCLC patients with lymph node metastasis when compared with patients without lymph node metastasis (36). Here, EPCAM is linked to metastatic malignant neoplasm in the lymph nodes.